Sign In
Buy ALNY
$297.69
+5.53 (+1.89%)
At Close: Jun 09, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present new data from its hypertension and
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference
08:00am, Tuesday, 05'th Aug 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord
Earnings Estimates Rising for Alnylam (ALNY): Will It Gain?
01:21pm, Monday, 04'th Aug 2025
Alnylam Pharmaceuticals (ALNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance
02:28pm, Friday, 01'st Aug 2025
Alnylam Pharmaceuticals Inc. ALNY reported upbeat second-quarter earnings and 2025 guidance on Thursday.
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
12:51pm, Friday, 01'st Aug 2025
Alnylam stock jumps 15% after a surprise Q2 profit, driven by soaring Amvuttra sales and raised 2025 revenue guidance.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
President Trump demands drugmakers slash prices within 60 days
06:54am, Friday, 01'st Aug 2025
CNBC's Joe Kernen reports on the latest news.
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call Transcript
04:47pm, Thursday, 31'st Jul 2025
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Christine Regan Akinc - Chief Corporate Communications Officer Jeffrey V. Po
Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast
03:36pm, Thursday, 31'st Jul 2025
The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. ALNY continue to outperform market expectations. Amid a backdrop of growing demand fo
Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
11:31am, Thursday, 31'st Jul 2025
The headline numbers for Alnylam (ALNY) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
10:17am, Thursday, 31'st Jul 2025
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.56 per share a ye
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress
08:00am, Thursday, 31'st Jul 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended J
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:07am, Thursday, 24'th Jul 2025
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam (ALNY) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Tuesday, 22'nd Jul 2025
Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results
08:00am, Thursday, 17'th Jul 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter end
